Robert Friedlander is the Founder and CEO of HELEXVA and currently serves as the Chair of the Scientific Advisory Board at NeuBase Therapeutics, Inc., focusing on developing new genetic medicines for diseases such as Myotonic Dystrophy and Huntington's Disease. They also hold the positions of Chair and Walter E. Dandy Professor at the University of Pittsburgh Neurosurgery and Chair of Neurosurgery at UPMC, roles they have maintained since 2010. Robert completed their Doctor of Medicine degree at Harvard Medical School and underwent neurosurgery training at Massachusetts General Hospital from 1991 to 1998. They are currently pursuing studies at Brandeis University.
Location
Pittsburgh, United States
This person is not in the org chart
This person is not in any teams
This person is not in any offices